The purpose of this study is to investigate whether combining FOLFIRINOX chemotherapy and stereotactic radiotherapy in patients with locally advanced pancreatic cancer leads to an increase in survival.

Inclusion Criteria:

• Cytological or histologically confirmation of pancreatic cancer.
• WHO performance status of 0 or 1
• ASA classification I or II
• Tumor considered locally advanced after diagnostic work-up including CT-imaging and diagnostic laparoscopy.
• No evidence of metastatic disease
• Largest tumor diameter < 7 cm x 7 cm x 7 cm
• Normal renal function (Creatinine ≥ 30 ml/min).
• Normal liver tests (bilirubin < 1.5 times normal; ALAT/ASAT < 5 times normal)
• Normal bone marrow function (WBC > 3.0 x 10e9/L, platelets > 100 x 10e9/L and hemoglobin > 5.6 mmol/l)
• Age > 18 years and < 75 years
• Written informed consent

Exclusion Criteria:

• Prior radiotherapy, chemotherapy or resection (bypass surgery allowed).
• Lymph node metastases from primary tumor outside the field of radiation.
• Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence.
• Pregnancy, breast feeding.
• Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.